Alkermes

676 articles with Alkermes

• Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

  3/23/2023

  Alkermes plc  (Nasdaq: ALKS) today announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI ® (olanzapine and samidorphan) in the peer-reviewed publication, the Journal of Clinical Psychiatry.

• Alkermes to Participate in the Stifel 2023 CNS Days

  3/15/2023

  Alkermes plc announced that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 9:00 a.m. ET.

• Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

  2/16/2023

  Alkermes plc reported financial results for the quarter and year ended Dec. 31, 2022 and provided financial expectations for 2023.

• Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023

  2/9/2023

  Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Thursday, Feb. 16, 2023 to discuss the company's fourth quarter and year-end 2022 financial results.

• Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

  1/17/2023

  Alkermes plc has been granted an Innovation Passport for the treatment of mucosal melanoma under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).

• Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference

  12/28/2022

  Alkermes plc announced that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference.

• Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

  11/30/2022

  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m. GMT).

• Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

  11/22/2022

  Alkermes plc announced that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET.

• Alkermes to Participate in the Stifel Healthcare Conference

  11/8/2022

  Alkermes plc announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022 at 8:00 a.m. ET.

• 

  Strategic Growth, IRA Drive Alkermes to Consider Spin-Out of Oncology Business

  11/2/2022

  Alkermes is exploring the potential spin-out of its cancer business into an independent, publicly traded company. Alkermes offered further details during an investor call Wednesday.

• Alkermes plc Reports Third Quarter 2022 Financial Results

  11/2/2022

  Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2022 and updated certain financial expectations for full-year 2022. Alkermes today also announced its intent, as approved by its Board of Directors (the Board), to explore a separation of its commercial-stage neuroscience business and development-stage oncology business.  

• Alkermes plc Announces Intent to Separate Oncology Business

  11/2/2022

  Alkermes plc today announced approval by its Board of Directors (the Board) to explore separating its commercial-stage neuroscience business and development-stage oncology business.

• Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

  10/26/2022

  Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Wednesday, Nov. 2, 2022 to discuss the company's third quarter financial results.

• Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case

  10/16/2022

  Acorda Therapeutics, Inc. announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC regarding licensing royalties relating to AMPYRA.

• Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program

  9/28/2022

  Alkermes plc announced that it is now accepting applications for its annual Alkermes Pathways Research Awards® program.

• Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress

  9/20/2022

  Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio at Psych Congress, which began on Sept. 17 and concludes today, Sept. 20 in New Orleans .

• 

  Tips for Managing a Multigenerational, Post-Pandemic Workforce

  8/24/2022

  While there has been a perception that young people are smarter or more creative, analyses from the Kellogg School of Management show most scientists make their breakthroughs later in life.

• Alkermes plc Reports Second Quarter 2022 Financial Results

  7/27/2022

  Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2022 and provided updated financial expectations for full-year 2022.

• Alkermes to Report Second Quarter Financial Results on July 27, 2022

  7/20/2022

  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 27, 2022 to discuss the company's second quarter financial results.

• Alkermes Announces Results of Annual General Meeting of Shareholders

  7/7/2022

  Alkermes plc announced the results of its 2022 Annual General Meeting of Shareholders held July 7, 2022.